Valibose An α-glucosidase inhibitor potentially for the treatment of diabetes. Valibose significantly decreased postprandial and fasting blood glucose, urine glucose, and reduced the levels of serum fructosamine. Valibose also decreased plasma triglyceride and cholesterol levels. Valibose ameliorated metabolic disturbance of glucose and lipids. In addition, valibose markedly reduced level of serum NAG and BUN, and decreased the weight index of kidney. References: Liu Q, Liu SN, Sun SJ, Shen ZF. [Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats]. Yao Xue Xue Bao. 2013 Aug;48(8):1227-32. Chinese. PubMed PMID: 24187828.

纯度：≥98%

CAS：83470-79-5